EQS-Adhoc: Relief Therapeutics Holding SA: Relief Reports Full-Year 2021 Results and Provides Corporate Update

Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Reports Full-Year 2021 Results and Provides Corporate Update 31-March-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant

Related Keywords

Georgia ,United States ,Germany ,Hungary ,United Kingdom ,Geneva ,Genè ,Switzerland ,Italy ,Secheron ,Switzerland General ,Ireland ,San Francisco ,California ,Hungarian ,American ,Swiss ,Paolo Galfetti ,Tom Plitz ,Anthonym Kim ,Michael Miller ,Patrice Jean ,Raghuram Selvaraju ,Marco Marotta ,Jeremy Meinen ,Christopher Wick ,David Schoenfeld ,Nermeen Varawalla ,Advita Lifescience Gmbh ,Advita Lifescience Gmb ,Jack Weinstein ,Relief Therapeutics Holding Sa Key ,Linkedin ,National Institute Of Allergy ,Us National Institutes Of Health ,Rx Communications Group ,Meta Healthcare Ltd ,Nasdaq ,Trademark Office ,Hungarian Health Officials ,Acer Therapeutics Inc ,News Service ,Drug Administration ,Pharma Research ,Swiss Exchange ,Nrx Pharmaceuticals Inc ,Exchange Commission ,Key Clinical Development ,Nephron Pharmaceuticals Inc ,Securities Exchange ,Relief Therapeutics Holding ,European Medicines Agency ,Neurorx Inc ,Healthcare Products Regulatory Agency ,Swiss Patent Office ,Group Swiss ,Reports Full Year ,Provides Corporate Update ,Provides Corporate ,Registration Statement ,Nasdaq Stock Market ,Acer Therapeutics ,New Drug Application ,Prescription Drug User Fee Act ,Marketing Authorization Application ,Maple Syrup Urine Disease ,Orphan Drug Designation ,Chief Medical Officer ,Senior Vice President ,Senior Director ,Clinical Development Highlights ,Emergency Use Authorization ,Severely Ill Inpatients ,Access Protocol ,Prime Minister ,Data Safety Monitoring Board ,Investigational New Drug ,Nephron Pharmaceuticals ,Breakthrough Therapy Designation ,Respiratory Failure ,Central European ,Expanded Access ,Federal Right ,National Institute ,Infectious Diseases ,United States Patent ,Eastern Europe ,Quantum Leap Healthcare Collaborative ,Intestinal Peptide ,Drug Induced Pneumonitis ,License Agreement ,Patent Application ,Use Diclofenac ,Chief Executive Officer ,Relief Europe ,Vice President ,Chief Accounting Officer ,Chief Business Officer ,Depositary Receipt ,Securities Exchange Act ,Ended December ,Share Subscription Facility ,Vasoactive Intestinal Peptide ,Urea Cycle Disorders ,Maple Syrup Urine ,Financial Officer ,Communications Group ,Adhoc ,Relief ,Herapeutics ,Molding ,Reports ,Bull ,Ear ,021 ,Results ,Rovides ,Corporate ,Update ,